Maxim Group reiterated their buy rating on shares of Vistagen Therapeutics (NASDAQ:VTGN) in a report issued on Friday morning, AnalystRatings.com reports. They currently have a $1.00 target price on the stock.
VTGN has been the subject of a number of other research reports. Zacks Investment Research raised shares of Vistagen Therapeutics from a sell rating to a hold rating in a research note on Saturday, April 25th. ValuEngine raised shares of Vistagen Therapeutics from a hold rating to a buy rating in a research note on Tuesday, March 3rd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $0.85.
Vistagen Therapeutics stock opened at $0.54 on Friday. The company has a 50 day moving average price of $0.48 and a 200-day moving average price of $0.56. Vistagen Therapeutics has a fifty-two week low of $0.29 and a fifty-two week high of $1.49. The company has a market capitalization of $25.92 million, a PE ratio of -0.92 and a beta of 0.31.
Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Monday, June 29th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. As a group, research analysts expect that Vistagen Therapeutics will post -0.52 earnings per share for the current year.
A hedge fund recently bought a new stake in Vistagen Therapeutics stock. Advisor Group Holdings Inc. purchased a new position in shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 171,414 shares of the company’s stock, valued at approximately $75,000. Advisor Group Holdings Inc. owned approximately 0.35% of Vistagen Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 4.83% of the company’s stock.
About Vistagen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Further Reading: FinTech
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.